Board resignation

Moss, 13 May 2026 Reference is made to the stock exchange release regarding Vatne Capital’s notification of change in major shareholding. The company has been notified that Mr. Runar Vatne will resign as board member effective today.

IR contact: Njaal Kind, CFO njaal.kind@gentian.no +47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange announcement was published by Ole Sørlie, Business controller at Gentian Diagnostics ASA, on 13 May 2026 at 08:00 CET.

About Gentian Diagnostics Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.